Go Pro
NASDAQ:NTRB

Nutriband Q2 2025 Earnings Report

Nutriband logo
$3.08 -0.03 (-0.96%)
Closing price 07/20/2026 03:55 PM Eastern
Extended Trading
$3.02 -0.06 (-1.95%)
As of 07/20/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nutriband EPS Results

Actual EPS
-$0.12
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nutriband Revenue Results

Actual Revenue
$0.44 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nutriband Announcement Details

Quarter
Q2 2025
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Nutriband Earnings Headlines

Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
See More Nutriband Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nutriband? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nutriband and other key companies, straight to your email.

About Nutriband

Nutriband (NASDAQ:NTRB) develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

View Nutriband Profile